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Introduction: Anaplastic lymphoma kinase (ALK)-rearranged non–
small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but 
resistance develops. This study assessed the maximum-tolerated 
dose, safety, pharmacokinetics (PK), and antitumor activity of ceri-
tinib, a novel ALK inhibitor (ALKi), in Japanese patients with ALK-
rearranged malignancies.
Methods: This phase I, multicenter, open-label study (NCT01634763) 
enrolled adult patients with ALK-rearranged (by fluorescence in 
situ hybridization and/or immunohistochemistry) locally advanced/
metastatic malignancy that had progressed despite standard therapy. 
The study comprised two parts: dose escalation and dose expansion. 
Ceritinib (single-dose) was administered orally in the 3-day PK run-
in period, then once daily, in 21-day cycles. Adaptive dose escalations 
were guided by a Bayesian model.
Results: Twenty patients (80% with ALKi treatment history [ALKi-
pretreated]; 19 NSCLC; one inflammatory myofibroblastic tumor) 
received ceritinib 300 to 750 mg (19 during dose escalation, one in 
dose expansion). Two dose-limiting toxicities occurred: grade 3 lipase 
increase (600 mg); grade 3 drug-induced liver injury (750 mg). The 
most common adverse events were gastrointestinal (nausea: 95%; 
diarrhea, vomiting: 75%). Ceritinib PK profile was dose proportional 
across 300 to 750 mg dosages; steady state was reached by day 15. 
Overall response rate was 55% (11 of 20 patients). Among patients 
with NSCLC, partial response was observed in two of four ALKi-
naive patients, five of nine crizotinib-pretreated patients, two of four 
alectinib-pretreated patients, and one of two crizotinib and alectinib/
ASP3026 pretreated patients. The ASP3026-pretreated inflammatory 
myofibroblastic tumor patient achieved partial response.
Conclusions: Ceritinib maximum-tolerated dose was 750 mg once 
daily in Japanese patients. Antitumor activity was observed irrespec-
tive of prior ALKi treatment history. Dose expansion, examining the 
activity of ceritinib in alectinib-resistant patients, is ongoing.
Key Words: ALK rearranged, non–small-cell lung cancer, Ceritinib, 
Alectinib.
(J Thorac Oncol. 2015;10: 1058–1066)
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first discovered in anaplastic large cell lymphoma.1 
ALK gene rearrangements occur in a variety of human malig-
nancies, including non–small-cell lung cancer (NSCLC).2,3 
Overall, 2% to 7% of patients with NSCLC have ALK genetic 
alterations, with higher prevalence among nonsmokers, 
younger patients, and patients with adenocarcinomas.4–6 ALK 
gene rearrangement can trigger oncogenic signaling path-
ways, principally the extracellular signal-regulated kinase 
and signal transducer and activator of transcription 3 path-
ways.2 Inhibition of ALK by a tyrosine kinase inhibitor could 
lead to suppression of potential oncogenic drivers.
Crizotinib (Xalkori; Pfizer, Mission, KS) is an oral inhibi-
tor of ALK, c-MET, and ROS1 receptor tyrosine kinases, effec-
tive in patients with advanced, ALK-rearranged NSCLC, with 
overall response rates (ORRs) of approximately 60% across 
all studies, and median progression-free survival (PFS) of 8 to 
10 months.7–9 In an open-label phase III study, crizotinib was 
superior to standard chemotherapy in patients with previously 
treated, advanced, ALK-rearranged NSCLC (ORR, 65% versus 
20%; median PFS, 8 versus 3 mo, with crizotinib versus che-
motherapy).9 Although crizotinib has demonstrated therapeu-
tic efficacy, the majority of patients progress, typically within 
12 months, with the development of resistance.10 Acquired 
resistance has been observed in about one third of patients with 
ALK-rearranged NSCLC involving mutations within the ALK 
tyrosine kinase domain and/or amplification of the ALK fusion 
gene and/or activation of EGFR, KRAS, or c-KIT.10–13
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Alectinib (CH5424802/RO5424802; Chugai/Roche) is 
a selective, orally available ALK inhibitor.14 In a phase I/II 
study of alectinib in Japanese patients with ALK-rearranged 
NSCLC, an ORR of 93.5% was reported in patients who had 
not previously received an ALK inhibitor, with no dose-lim-
iting toxicities (DLTs) at the maximally administered dose of 
300 mg twice daily.15 Another phase I study, conducted in the 
United States, evaluated alectinib in patients with crizotinib-
refractory ALK-rearranged NSCLC, demonstrating an ORR 
of 55% (all cohorts), including both confirmed and uncon-
firmed responses, with DLTs occurring in the 900 mg twice-
daily cohort.16 The recommended phase II dose for alectinib 
was determined as 600 mg twice daily in the non-Japanese 
population16 and 300 mg twice daily in Japanese patients.15
Ceritinib (LDK378; Novartis Pharmaceuticals) is a 
novel, potent, orally active, small-molecule tyrosine kinase 
inhibitor of ALK. In enzyme-based assays, ceritinib inhib-
ited ALK with a half maximal inhibitory concentration (IC
50
) 
value of 0.20 nM. In an enzyme panel of 30 kinases, only three 
other kinases (IGF-1R [IC
50
 = 8 nM], InsR [IC
50
 = 7 nM], 
and STK22D [IC
50
 = 23 nM]) showed biochemical inhibition 
below 100 nM, demonstrating the potency and high selectivity 
of ceritinib. At the cellular level, in a panel of 18 kinases, ceri-
tinib inhibited ALK with an IC
50
 value less than 100 nM, con-
firming its high potency.17 Furthermore, ceritinib was found 
to be 20-fold more potent compared with crizotinib in inhibit-
ing ALK, and unlike crizotinib, it did not inhibit the kinase 
activity of c-MET. Ceritinib demonstrated marked antitumor 
activity in echinoderm microtubule-associated protein-like 4 
(EML4)-ALK xenograft models of NSCLC, including those 
exhibiting crizotinib resistance.18 These preclinical results 
suggested that ceritinib might exhibit antitumor activity in 
patients with ALK-rearranged NSCLC with crizotinib-resis-
tant and crizotinib-naive disease.
Accordingly, results from a first-in-human, dose-escala-
tion, phase I study of ceritinib (ASCEND-1; NCT01283516) in 
patients with ALK-rearranged malignancies have recently been 
published. The maximum-tolerated dose (MTD) of oral ceritinib 
was established as 750 mg once daily.19 Ceritinib demonstrated 
substantial clinical activity in patients with NSCLC treated at 
doses of 750 mg once daily, reporting PFS of 18.4 months (95% 
confidence interval, 11.1, nonestimable) in patients who were 
ALK inhibitor naive (n = 83) and 6.9 months (95% confidence 
interval, 5.6, 8.7) in patients previously treated with crizotinib 
(n = 163).20 The ORR was 61.8% in all patients (n = 246), 
72.3% in patients who were ALK inhibitor naive, and 56.4% in 
patients previously treated with crizotinib.20
More recently, ceritinib activity has also been shown 
against cell lines harboring alectinib-resistant mutations, 
including a patient-derived cell line.21 Further, ceritinib treat-
ment of a patient who had progressed on alectinib following 
an initial response resulted in significant tumor regression, 
with a confirmed partial response (PR) more than 7 months.21 
These data suggest that ceritinib may show activity in patients 
who relapse on this second-generation ALK inhibitor, as well 
as in patients who are resistant to crizotinib.
This phase I, multicenter, open-label study (NCT01634763) 
was conducted to determine the MTD, safety, pharmacokinetics 
(PK), and antitumor activity of ceritinib in Japanese patients 
with ALK-rearranged NSCLC or other tumors harboring an ALK 
gene alteration. In addition, given the recent data in the literature 
on ceritinib efficacy in alectinib-resistant tumors and consequent 
interest in the potential for sequential therapy with ALK inhibi-
tors,21 further details on efficacy and safety in patients who had 
previously relapsed during treatment with alectinib are provided.
PATIENTS AND METHODS
Study Population
Adult patients (≥18 yr) with locally advanced or meta-
static malignancy harboring genetic alterations in ALK, which 
had progressed despite standard therapy or for which no 
effective standard therapy exists, were included in this study. 
Genetic translocation in ALK was detected by fluorescence 
in situ hybridization (FISH) in at least 15% of tumor cells 
in patients with NSCLC; in other tumors, overexpression of 
ALK protein by immunohistochemistry was considered indic-
ative of a genetic alteration in ALK. Other eligibility criteria 
included measurable or nonmeasurable disease and Eastern 
Cooperative Oncology Group performance status of 0 to 2. 
Patients with NSCLC that had progressed during prior therapy 
with alectinib were enrolled to the dose-expansion part of the 
study.
Key exclusion criteria included patients with uncon-
trolled or symptomatic central nervous system metastases 
requiring increasing doses of steroids; patients with uncon-
trolled nausea, vomiting, or diarrhea of Common Terminology 
Criteria for Adverse Events (version 4.03) grade more than 1; 
and history of or current second malignancy and/or interstitial 
lung disease.
The study protocol and all amendments were reviewed 
by the institutional review board for each investigational site. 
This study was conducted according to the ethical principles 
of the Declaration of Helsinki and the Good Clinical Practice 
guidelines of the International Conference on Harmonisation. 
Institutional review board–approved informed consent was 
obtained from each patient in writing at screening.
Study Design
The primary objective of this study was to determine 
the MTD and/or the recommended dose (RD) of oral ceritinib 
in Japanese patients with ALK-rearranged tumors. Secondary 
objectives included assessment of the overall safety, tolerabil-
ity, and single- and multiple-dose PK profile of ceritinib, as 
well as investigation of its preliminary antitumor efficacy at 
MTD/RD.
The study was divided into two parts: dose escalation 
and dose expansion at the MTD/RD. In each dose cohort 
of the dose-escalation part, three to six patients were to be 
enrolled, with at least six patients at the MTD/RD. In addition, 
at least six patients were to be enrolled in the dose-expansion 
part, after determination of the MTD/RD. Dose-escalation 
decisions, including MTD/RD determination, were made 
by the Principal Investigators and Novartis study personnel, 
based on available toxicity information (including DLTs and 
other adverse events [AEs] during cycle 1), PK information, 
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and recommendations from the Bayesian logistic regression 
model (BLRM). Updated safety data from ongoing patients, 
including data in later cycles, were also considered.
Ceritinib was administered orally as a single dose in the 
3-day PK run-in period, followed by once-daily dosing in con-
tinuous 21-day cycles. Based on the available safety and effi-
cacy data from the global, first-in-human, ASCEND-1 study 
at the time of protocol writing, ceritinib was well tolerated at 
doses up to 500 mg once daily, with no DLTs at the 300 mg 
once-daily dose. Furthermore, based on predictions from the 
BLRM, the MTD was more than 700 mg once daily, with a 
low probability of overdose at the 600 mg once-daily dose. 
Therefore, the starting dose of ceritinib selected for this study 
was 300 mg once daily. Patients continued treatment until 
unacceptable toxicity, disease progression, or withdrawal of 
consent. Treatment beyond disease progression was permitted 
if there was evidence of clinical benefit, as assessed by the 
principal investigator, such as disease shrinkage at other sites 
or symptomatic improvement.
To further address the safety, antitumor activity, and 
PK profile of ceritinib treatment in patients previously treated 
with alectinib, the dose-expansion part of this study is focused 
on patients with ALK-rearranged NSCLC who progressed on 
alectinib treatment.
Assessments
DLTs were assessed during the first cycle (including the 
PK run-in period) of ceritinib treatment in the dose-escalation 
part. AEs were assessed according to Common Terminology 
Criteria for Adverse Events version 4.03. Blood samples 
were collected for the assessment of PK parameters follow-
ing ceritinib treatment. Tumor response evaluations were per-
formed by local investigators using computerized tomography 
or magnetic resonance imaging according to the Response 
Evaluation Criteria In Solid Tumors version 1.1 at baseline and 
subsequently on day 1 of every odd cycle (within –3 to +14 
days), except for cycle 1 day 1, until discontinuation from the 
study. Brain magnetic resonance imaging or head computer-
ized tomography were performed in all patients with NSCLC 
due to the high incidence of brain metastases; metastatic dis-
ease sites were followed at scheduled visits using appropriate 
imaging, as clinically indicated.
Statistical Analysis
An adaptive BLRM employing the escalation with 
overdose control (EWOC) principle was used to make dose 
recommendations and estimate the MTD/RD.22 According to 
the EWOC principle, the potential doses recommended for 
the successive cohort in the dose-escalation part and the esti-
mated MTD/RD for the dose-expansion part must have less 
than 25% posterior probability of DLT in the excessive toxic-
ity interval (≥33% to ≤100%). After each cohort of patients 
in the dose-escalation part, the posterior distributions for the 
probabilities of DLT at different dose levels were obtained 
using the BLRM, and in general, the dose recommended for 
the successive cohort or estimated as MTD/RD was the one 
with the highest posterior probability of DLT rate falling in 
the targeted toxicity interval (≥16% to <33%), among the 
doses fulfilling the EWOC principle.
Safety data were summarized for all patients (ALK-
rearranged NSCLC and other tumors) who received at least 
one dose of ceritinib. The PK analysis was summarized for all 
patients who received at least one dose of ceritinib and had at 
least one evaluable PK sample. Efficacy data were analyzed 
for all patients with NSCLC who had received the first dose 
of ceritinib at least 18 weeks before the analysis cutoff date. 
Data from patients enrolled in the dose-expansion part were 
pooled with data from patients receiving the same dose level 
in the dose-escalation part of the study. The ORR and disease 
control rate were summarized along with the exact (Clopper–
Pearson) 95% confidence intervals. The data cutoff date was 
July 4, 2014, for safety and efficacy data. For PK analyses, the 
data cutoff date was August 2, 2013, including only patients in 
the dose-escalation part of the study. Enrollment for the dose-
expansion part is ongoing.
RESULTS
Patient Disposition
A total of 19 patients were enrolled and treated with 
ceritinib at doses of 300 mg (n = 3), 450 mg (n = 6), 600 mg 
(n = 4), and 750 mg (n = 6), in the dose-escalation part of this 
study. In addition, one patient was enrolled in the dose-expan-
sion part of the study and is included in the 750-mg group for 
all analyses presented, apart from PK analyses. Median dura-
tion of exposure to ceritinib was 32.1 weeks (range, 0.1–86.7 
weeks). At the time of data cutoff, 19 patients (95%) had dis-
continued treatment. The most common reason for discontin-
uation was progression (12 patients [60%]—includes patients 
with response prior to disease progression), eight of whom 
were treated at doses less than 750 mg once daily. AEs led to 
discontinuation in a further two patients (10%). One patient 
discontinued treatment due to drug-induced liver injury that 
was reported as a DLT; the other patient discontinued due 
to cholangitis and increased hepatic enzyme, both of which 
were considered to be related to biliary stent malfunction, 
but not to the study drug. Two patients died during the study, 
due to disease progression; neither of the deaths was consid-
ered related to the study drug. Both patients had metastatic 
ALK-rearranged NSCLC at study entry. At the time of death, 
one patient had ongoing hydrocephalus; the other patient had 
respiratory failure.
Demographics and Baseline 
Disease Characteristics
Overall, 55% of patients were female, and 90% had an 
Eastern Cooperative Oncology Group performance status of up 
to 1 (Table 1). Nineteen patients (95%) had NSCLC, and one 
patient (5%) had inflammatory myofibroblastic tumor (IMT). 
ALK positivity was confirmed by immunohistochemistry in 
the patients with IMT; ALK rearrangement was confirmed by 
FISH in all 19 patients with NSCLC. Among 19 patients with 
NSCLC, 17 (89%) were diagnosed with adenocarcinoma. The 
majority of patients (80%) had received prior ALK inhibitors: 
45% crizotinib only; 25% other ALK inhibitor (alectinib or 
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ASP3026); and 10% both crizotinib and other ALK inhibitor. 
All 19 patients with NSCLC had measurable disease accord-
ing to Response Evaluation Criteria In Solid Tumors v 1.1.
Dose Escalation and Toxicity
During dose escalation, two DLTs were reported in two 
patients. Grade 3 lipase increase (>2.0–5.0 × upper limit of 
normal [ULN]) occurred in one patient treated with ceritinib 
600 mg once daily. The patient experienced nausea, vomiting, 
and gastrointestinal pain before and during the grade 3 lipase 
increase; however, the investigator assessed that these events 
were not the symptoms of pancreatitis. The event resolved 
without medication, after ceritinib was interrupted. Ceritinib 
was resumed at a dose of 450 mg once daily. Grade 3 drug-
induced liver injury (elevated bilirubin [>3.0–10.0 × ULN], 
ALP, alanine aminotransferase [ALT], and aspartate transami-
nase [>5.0–20.0 × ULN]) occurred in one patient treated with 
ceritinib 750 mg once daily; the condition improved after ceri-
tinib was permanently discontinued. Based on these findings, 
the MTD of ceritinib in Japanese patients was established as 
750 mg once daily. The posterior probability of DLT rate being 
in the excessive toxicity interval (≥33% to ≤100%) at the 750-
mg once-daily dose was 7.3%, which fulfilled the EWOC 
principle (<25%).
All patients experienced one or more drug-related AE. 
The most common AEs were nausea (95%), diarrhea (75%), 
and vomiting (75%) (Table 2). Sixteen patients (80%) reported 
grade 3/4 AEs, the most common of which were increased 
ALT and tumor pain, each of which occurred in two patients. 
Ten patients (50%) reported grade 3/4 AEs suspected to be 
drug related, the most common of which was increased ALT 
(two patients [10%]) (Table 2). Aside from DLTs, no other 
drug-related AEs lead to discontinuation from the study. Nine 
patients (45%) experienced at least one dose reduction and 
11 patients (55%) at least one dose interruption due to AEs, 
with most occurring in patients treated at 750 mg dose (5 of 9 
and 5 of 11, respectively) (Supplementary Digital Content 1, 
http://links.lww.com/JTO/A838, shows dose amendments due 
to AEs according to dose). Overall, ceritinib had an acceptable 
tolerability profile in Japanese patients, with no treatment-
related deaths reported.
Pharmacokinetics
PK analyses revealed that ceritinib exposure 
increased with dose across the 300 to 750 mg once-daily 
range (Table 3). In the PK run-in period, the relation-
ship between ceritinib dose and PK parameters (maxi-
mum plasma concentration [C
max
] and area under plasma 
TABLE 1.  Baseline Characteristics
Demographic Variable
Ceritinib Dose
All  
Patients
300 mg  
Once Daily
450 mg  
Once Daily
600 mg  
Once Daily
750 mg  
Once Daily
n = 3 n = 6 n = 4 n = 7 N = 20
Age, yr
  Median (range) 51 (45–56) 37 (29–67) 39 (34–61) 45 (38–68) 44 (29–68)
  <65, n (%) 3 (100) 5 (83) 4 (100) 6 (86) 18 (90)
  ≥65, n (%) 0 1 (17) 0 1 (14) 2 (10)
Sex, n (%)
  Female 3 (100) 5 (83) 2 (50) 1 (14) 11 (55)
  Male 0 1 (17) 2 (50) 6 (86) 9 (45)
ECOG performance status, n (%)
  0 2 (67) 2 (33) 1 (25) 3 (43) 8 (40)
  1 1 (33) 2 (33) 3 (75) 4 (57) 10 (50)
  2 0 2 (33) 0 0 2 (10)
Baseline brain metastases, n (%) 1 (33) 4 (67) 3 (75) 0 8 (40)
Prior ALK inhibitor, n (%)
  Crizotinib only 1 (33) 4 (66) 2 (50) 2 (29) 9 (45)
  Other ALK inhibitor only 1 (33) 0 1 (25) 3 (43) 5 (25)
  Both crizotinib and other ALK inhibitor 0 1 (17) 1 (25) 0 2 (10)
  ALK inhibitor naive 1 (33) 1 (17) 0 2 (29) 4 (20)
Median time since last dose of prior ALK inhibitor to start 
of treatment, days (range)
80 (20–140) 73 (16–110) 16 (16–17) 17 (15–34) 17 (15–140)
Prior ALK inhibitor as last therapy, n (%) 1 (33) 3 (50) 4 (100) 5 (71) 13 (65)
Type of ALK-rearranged tumors
  NSCLC 3 (100) 6 (100) 4 (100) 6 (86) 19 (95)
  IMT 0 0 0 1 (14) 1 (5)
ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; IMT, inflammatory myofibroblastic tumor; NSCLC, non–small-cell lung cancer.
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concentration versus time curve over a dosing interval 
[AUC
0–24
]) was analyzed. Although interindividual variabil-
ity was observed, C
max
 and AUC
0–24
 increased in an approxi-
mately dose proportional manner, with exponent near unity 
(0.909 and 1.04, respectively) in a power model assuming a 
natural log (ln)-normal distribution: ln(parameter) = expo-
nent × ln(dose) + constant (Graph a, Supplementary Digital 
Content 2, http://links.lww.com/JTO/A838, showing the 
dose relationship of AUC
0–24
). In addition, in cycle 1 day 8 
and cycle 2 day 1, C
max
 and AUC
0–24
 tended to increase with 
ascending dose (Table 3). The elimination half-life calcu-
lated at each dose in the 3-day PK run-in period was 22 to 
33 hours. Median time to reach maximum plasma concen-
tration (T
max
) was 2 to 7 hours across the tested doses and 
profile days. Based on trough concentration versus time 
profiles, at cycle 1 day 15, ceritinib plasma concentration 
appeared to reach steady state (data not shown). Graph b 
(Supplementary Digital Content 2, http://links.lww.com/
JTO/A838) shows the steady-state ceritinib plasma concen-
tration versus time profile (cycle 2 day 1). At the ceritinib 
MTD of 750 mg, AUC
0–24
 was 26,400 ng·hr/mL (Graph, 
Supplementary Digital Content 2, http://links.lww.com/
JTO/A838) (Table 3). Geometric mean for the accumula-
tion ratio was 5.41 to 19.5 at cycle 1 day 8 and 6.78 to 21.5 
at cycle 2 day 1.
Efficacy
Efficacy of ceritinib treatment in all patients.
Based on investigator assessment across all dose 
groups, the ORR and disease control rate among patients with 
NSCLC were 10 of 19 (53%) and 13 of 19 (68%), respectively 
(Table 4). Of four patients with ALK-rearranged NSCLC not 
previously treated with an ALK inhibitor, two patients had a 
confirmed PR.
Fifteen patients with ALK-rearranged NSCLC had pre-
viously received an ALK inhibitor (crizotinib, alectinib, or 
ASP3026), with a median time from last dose of prior ALK 
inhibitor to ceritinib treatment of 17 days (range, 15–140). 
All patients discontinued at least one prior ALK inhibitor 
due to disease progression; the patient who had received 
both alectinib and crizotinib discontinued alectinib due to 
disease progression and crizotinib due to an unknown rea-
son, while the patient receiving ASP3026 and crizotinib 
discontinued both drugs due to disease progression. Among 
the 15 patients previously treated with ALK inhibitors, 
eight (53%) had PR, including five of nine patients previ-
ously treated with crizotinib only, two of four patients pre-
viously treated with alectinib only, and one of two patients 
previously treated with both crizotinib and either alectinib or 
ASP3026 (the patient with PR was previously treated with 
crizotinib and ASP3026). The patient with IMT in the ceri-
tinib 750 mg once-daily group, who was previously treated 
with ASP3026, achieved PR.
Among 19 patients with ALK-rearranged NSCLC 
who had measurable disease at baseline, 16 patients had at 
least one valid postbaseline assessment. In the remaining 
three NSCLC patients, a valid postbaseline assessment was 
unavailable due to early withdrawal from the study (n = 2) 
or a change in imaging modality (n = 1). Of the 16 evalu-
able patients, 15 showed a reduction in the size of target 
lesions (Fig. 1). Responses occurred regardless of the type 
of prior ALK inhibitor administered (crizotinib, alectinib, or 
ASP3026).
TABLE 2.  Adverse Events (≥20% for All Grades) Considered to Be Study Drug Related
Preferred Term
Ceritinib Dose
All Patients  
(N = 20)
300 mg  
Once Daily (n = 3)
450 mg  
Once Daily (n = 6)
600 mg  
Once Daily (n = 4)
750 mg  
Once Daily (n = 7)
All Grades, 
n (%)
Grade 3/4, 
 n (%)
All Grades, 
n (%)
Grade 3/4, 
n (%)
All Grades, 
n (%)
Grade 3/4, 
n (%)
All Grades, 
n (%)
Grade 3/4, 
n (%)
All Grades, 
n (%)
Grade 3/4, 
n (%)
Nausea 3 (100) 0 6 (100) 0 4 (100) 0 6 (86) 1 (14) 19 (95) 1 (5)
Diarrhea 3 (100) 0 2 (33) 0 4 (100) 0 6 (86) 0 15 (75) 0
Vomiting 1 (33) 0 6 (100) 0 4 (100) 0 4 (57) 0 15 (75) 0
Increased blood creatinine 3 (100) 0 3 (50) 0 1 (25) 0 5 (71) 0 12 (60) 0
Decreased appetite 0 0 3 (50) 0 3 (75) 0 4 (57) 0 10 (50) 0
Fatigue 0 0 2 (33) 0 3 (75) 0 3 (43) 0 8 (40) 0
Abdominal pain 2 (67) 0 1 (17) 0 0 0 2 (29) 0 5 (25) 0
Increased alanine 
aminotransferase
0 0 2 (33) 0 1 (25) 1 (25.0) 1 (14) 1 (14) 4 (20) 2 (10)
Increased aspartate 
aminotransferase
0 0 2 (33) 0 1 (25) 1 (25.0) 1 (14) 0 4 (20) 1 (5)
Abnormal hepatic function 0 0 0 0 1 (25) 0 3 (43) 1 (14) 4 (20) 1 (5)
Hyperuricemia 0 0 0 0 0 0 4 (57) 0 4 (20) 0
Neutropenia 2 (67) 0 2 (33) 0 0 0 0 0 4 (20) 0
Rash 0 0 3 (50) 0 0 0 1 (14) 0 4 (20) 0
Maculopapular rash 1 (33) 0 1 (17) 0 1 (25) 0 1 (14) 0 4 (20) 0
Stomatitis 1 (33) 0 2 (33) 0 1 (25) 0 0 0 4 (20) 0
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Efficacy of ceritinib treatment in patients 
previously treated with alectinib.
PRs were observed in two of five patients previously 
treated with alectinib, neither of whom had brain metastases 
at baseline. Patient 2002 had a duration of response of 4.2 
months, with ceritinib administered at a dose of 300 mg once 
daily for 6.1 months. Figure 2 shows preceritinib and 5 months 
postceritinib treatment scan images, illustrating regression of 
the target lesion. Ceritinib was permanently discontinued after 
6.1 months due to progression in nontarget lesions (bone) and 
pleural effusion. Patient 3008 also achieved PR, with a dura-
tion of response of 9.5 months. Ceritinib was administered 
for 18.1 months at a dose of 750 mg once daily. Treatment 
was discontinued due to progressive disease. Clinical benefit 
with stable disease was also achieved in one patient, 3009, 
treated at 750 mg once daily. The patient, who did not have 
baseline brain metastases, was treated for 3.9 months before 
discontinuing due to progression of a new lesion in the brain 
(Supplementary Digital Content 3, http://links.lww.com/JTO/
A838, which shows the demographics, disposition, and effi-
cacy results in patients previously treated with alectinib).
Two of the five patients pretreated with alectinib had 
progressive disease following ceritinib treatment (1003 and 
3004). Patient 1003 received ceritinib 600 mg once daily for 1.4 
months before discontinuing due to progression of nontarget 
lesion (hilar lymph node) at day 45. Of note, ceritinib treatment 
was temporarily interrupted in this patient (day 25–36) due to 
grade 3 lipase increase. Patient 3004 had progressive disease 
TABLE 3.  Pharmacokinetic Parameters of Ceritinib
Dose (mg Once Daily) Day n T
max
 (hr) C
max
 (ng/mL) AUC
0–24
 (ng·hr/mL) T
1/2
 (hr)
300 (n = 3) PK run-in 2 5.10 168 (3) 2760 (33) 22.1 (3.4)
Cycle 1 day 8 3 3.00 537 (208) 10,700 (4950) NA
Cycle 2 day 1 2 5.98 867 (59) NA NA
450 (n = 6) PK run-in 5 5.88 76 (68) 1030 (963) 26.0 (6.3)a
Cycle 1 day 8 5 3.97 858 (215) 18,400 (4010)b NA
Cycle 2 day 1 5 5.95 982 (102) 20,900 (3990)c NA
600 (n = 4) PK run-in 4 5.97 215 (196) 3710 (3590) 30.7 (3.6)
Cycle 1 day 8 4 3.44 1060 (633) 16,600 (10,500)c NA
Cycle 2 day 1 4 4.93 1150 (592) 21,400 (15,300)a NA
750 (n = 6) PK run-in 6 5.98 206 (75) 3590 (1680) 33.4 (4.3)d
Cycle 1 day 8 6 6.96 1220 (212) 25,700 (4440)d NA
Cycle 2 day 1 3 1.93 1470 (375) 26,400 (5810)a NA
Values represent median for T
max
 and mean (SD) for C
max
, AUC
0–24
, and T
1/2
.
an = 2.
bn = 4.
cn = 3.
dn = 5.
AUC
0–24
, area under the plasma concentration versus time curve over the dosing interval; C
max
, maximum plasma concentration; NA, not applicable; PK, pharmacokinetic; T
1/2
, 
half-life; T
max
, time at which maximum plasma concentration is achieved.
TABLE 4.  Best Overall Response with Ceritinib in Patients with ALK-Rearranged NSCLC (RECIST Version 1.1)
Best Overall Response, n (%)
Ceritinib Dose
300 mg Once Daily 450 mg Once Daily 600 mg Once Daily 750 mg Once Daily
n = 3 n = 6 n = 4 n = 6
CR 0 0 0 0
PR 3 (100) 3 (50) 2 (50) 2 (33)
Stable diseasea 0 1 (17) 0 2 (33)
Progressive disease 0 1 (17) 2 (50) 0
Unknown 0 1 (17) 0 2 (33)
ORR (CR + PR) 3 (100) 3 (50) 2 (50) 2 (33)
  95% CI 29.2–100.0 11.8–88.2 6.8–93.2 4.3–77.7
Disease control rate  
(CR or PR or stable disease)
3 (100) 4 (67) 2 (50) 4 (67)
  95% CI 29.2–100.0 22.3–95.7 6.8–93.2 22.3–95.7
aTwo of three patients achieved an unconfirmed PR (one treated with 450 mg once daily and one with 750 mg once daily).
ALK, anaplastic lymphoma kinase; CI, confidence interval; CR, complete response; NSCLC, non–small-cell lung cancer; ORR, overall response rate; PR, partial response; 
RECIST, Response Evaluation Criteria in Solid Tumors.
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in a brain metastasis (nontarget lesion) after 1.7 months of 
treatment. Nevertheless, this patient was benefitting from treat-
ment and continued on ceritinib for a further 6.8 months before 
discontinuing after a total of 8.5 months of ceritinib (600 mg 
once daily for 6.3 mo and 450 mg once daily for 2.2 mo). Of 
note, the brain lesion was present at ceritinib treatment onset, 
and the patient received no treatment for brain metastases dur-
ing the study. Figure 2 shows scan images of the target lesion 
preceritinib and 12 weeks postceritinib, demonstrating some 
regression in the target lesion, despite progression in the brain. 
This patient discontinued treatment due to AEs (Supplementary 
Digital Content 3, http://links.lww.com/JTO/A838).
DISCUSSION
The results of this phase I study established the MTD of 
ceritinib at 750 mg once daily in Japanese patients with ALK-
rearranged tumors, including 19 patients with NSCLC and 
one with IMT. Ten of 19 patients with NSCLC (53%) achieved 
PR; furthermore, the patient with IMT also achieved PR.
Overall, the safety profile of ceritinib was accept-
able, with no treatment-related deaths. The safety profile (all 
grades) of ceritinib in Japanese patients was similar to that 
seen in the Asian subset of patients from the ASCEND-1 
study of ceritinib, with gastrointestinal AEs (nausea, diarrhea, 
and vomiting) having the highest incidence, though most were 
grade 1 to 2. Gastrointestinal AEs (including nausea, diarrhea, 
and vomiting) were also common (39–56%) with crizotinib.7 
The incidence of drug-related grade 3/4 AEs was 50% in this 
study, 49% in the ASCEND-1 study of ceritinib,19 and 24% 
with crizotinib.7
In this study, ceritinib plasma concentration appeared to 
reach steady state by day 15, and its PK profile was dose pro-
portional for the 300 to 750 mg once-daily dose range. In the 
ASCEND-1 study, there were no significant ethnic differences 
in PK parameters between Asian and non-Asian patients, 
although ceritinib showed a modest increase (<30%) in expo-
sure in Asian patients compared with non-Asian patients.23 
In this study, exposure was numerically higher (<30%) com-
pared with the Asian patients in ASCEND-1; however, patient 
numbers were limited (n = 3).
The ORR with ceritinib in Japanese patients with ALK-
rearranged NSCLC (10 of 19 patients, 53%) appeared lower 
compared with that observed in a subset of Asian patients from 
the ASCEND-1 study of ceritinib (56 of 82 patients, 68%). 
However, the numbers of patients are small, and there were dif-
ferences in baseline characteristics between the Asian popula-
tion of ASCEND-1 and Japanese patients with NSCLC enrolled 
in this study (e.g., >3 prior antineoplastic medications: 40% 
versus 26%; ALK inhibitor pretreatment: 57% versus 80%, for 
Asian patients in ASCEND-1 versus Japanese patients).23
In this study, ceritinib demonstrated clinical benefit in 
three (two PR and one stable disease) of five Japanese patients 
with recurrence or relapse after alectinib. In a phase I/II study 
of alectinib in Japanese patients with advanced, ALK-rearranged 
NSCLC who were ALK inhibitor naive (ALK confirmed by both 
immunohistochemistry and FISH), ORR was 93.5%.15 Ceritinib 
efficacy in alectinib-resistant patients could be a consequence 
of specific mutations that impair alectinib binding to ALK, but 
FIGURE 1.  Best percentage change from baseline with ceritinib, by dose group.
FIGURE 2.  Pre- and postceritinib treatment scan images in 
two patients previously treated with alectinib.
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not ceritinib, which is structurally distinct.21 Consistent with this, 
specific ALK resistance mutations have been shown to differen-
tially alter the IC
50
 values for different ALK inhibitors, such that 
one inhibitor shows greater activity over others.18,21
Ceritinib also demonstrated activity in this study in 
Japanese patients who had relapsed on crizotinib treatment. 
Ceritinib clinical activity in Japanese patients with crizo-
tinib-resistant ALK-rearranged tumors was consistent with 
the ASCEND-1 study.9 This may reflect the greater potency 
of ceritinib compared with crizotinib, which was observed 
in preclinical studies,18 and its ability to inhibit EML4-ALK 
harboring kinase-domain mutations known to be resistant to 
crizotinib, including L1196M.17,24
In patients with NSCLC treated with ALK inhibitors, 
acquired resistance is an ongoing challenge, potentially limit-
ing the transformative impact of these drugs on patients.10,21,25 
Resistance occurs due to secondary mutations in the ALK tyro-
sine kinase domain and ALK gene amplification.10,11,24 Most 
notably, the gatekeeper L1196M substitution has been shown to 
confer resistance to crizotinib.10,11,26 There may be differences 
in the efficacy of different ALK inhibitors for treating patients 
with certain resistance mutations; for example, alectinib was 
relatively less potent against L1196M, G1202R, and 1151Tins 
EML4-ALK than against S1206Y EML4-ALK,10 and ASP3026 
was less potent compared with crizotinib and alectinib against 
wild-type EML4-ALK but relatively more potent against 
G1202R.10 These data suggest that patients who develop resis-
tance to one or two ALK inhibitors through particular ALK 
mutations may still respond to other ALK inhibitors, such as 
ceritinib, with differing specificity for ALK. As a result of these 
considerations, although specific resistance mutations for each 
patient were not identified in this study, the study protocol was 
amended to focus on patients with NSCLC that has progressed 
since treatment with alectinib in the dose-expansion part. The 
observed ceritinib activity in patients previously treated with 
alectinib reported here supports this approach.
The results of this study suggest that ceritinib is active 
in Japanese patients with tumors harboring ALK rearrange-
ments, including those patients who have received prior treat-
ment with other ALK inhibitors.
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